The mathematical analysis of plasma HIV-1 viral load decay after the initiation of antiretroviral therapy has led to a number of important insights about the dynamics of HIV-1 infection, but not to a cure. Modeling, coupled to analysis of clinical data, suggested that with 100% effective therapy HIV could be eliminated from both short- and long-lived productively infected cell populations. Here, we propose to examine a set of problems related to the hurdles that have been encountered to eradicating HIV and thee development of effective HIV vaccines. We will pursue these ends by a combination of modeling and collaboration with experimental groups. In particular, we plan to continue to develop new viral dynamic models and use them to analyze both animal and patient data. Current HIV/SIV models have done a very poor job of realistically describing, the host immune response. Building on previous work, we plan to develop models that incorporate both cytolytic and noncytolytic CD8 responses to HIV. With vaccine trial data, we will look at the effects of elevated levels of antigen specific CD8 cells on the subsequent dynamics of viral growth upon SHIV/SIV challenge. We will model the effects of challenge dose and examine the reason why low-dose challenge frequently does not lead to infection. Natural antibody or other innate mechanisms may be at play here, and we will incorporate antibody responses into primary infection models. Other areas also will be explored such as Infection of gut associated lymphoid tissue, the possibility of cells being multiply infected, and issues of the stability of the latent reservoir.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37AI028433-17
Application #
7197086
Study Section
Special Emphasis Panel (NSS)
Program Officer
Gezmu, Misrak
Project Start
1990-07-01
Project End
2012-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
17
Fiscal Year
2007
Total Cost
$270,114
Indirect Cost
Name
Los Alamos National Lab
Department
Type
DUNS #
175252894
City
Los Alamos
State
NM
Country
United States
Zip Code
87545
Canini, Laetitia; Lemenuel-Diot, Annabelle; Brennan, Barbara J et al. (2018) A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor. Antivir Ther 23:353-361
Liu, Donglai; Wang, Chu; Hora, Bhavna et al. (2017) A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology 14:46
Osuna, Christa E; Lim, So-Yon; Deleage, Claire et al. (2016) Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat Med 22:1448-1455
Canini, Laetitia; Guedj, Jeremie; Chatterjee, Anushree et al. (2016) Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. Antivir Ther 21:297-306
Smith, Nicola M G; Mlcochova, Petra; Watters, Sarah A et al. (2015) Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. Clin Infect Dis 61:120-8
Johnson, Susan; Bergthaler, Andreas; Graw, Frederik et al. (2015) Protective efficacy of individual CD8+ T cell specificities in chronic viral infection. J Immunol 194:1755-62
Song, Hongshuo; Hora, Bhavna; Bhattacharya, Tanmoy et al. (2014) Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus. PLoS One 9:e102734
Fletcher, Courtney V; Staskus, Kathryn; Wietgrefe, Stephen W et al. (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111:2307-12
Althaus, Christian L; Joos, Beda; Perelson, Alan S et al. (2014) Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. PLoS Comput Biol 10:e1003871
Sherman, Kenneth E; Guedj, Jeremie; Shata, Mohamed Tarek et al. (2014) Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Sci Transl Med 6:246ra98

Showing the most recent 10 out of 223 publications